Abstract：
Chronic rhinosinusitis with nasal polyp (CRSwNP) is one of the major phenotypes of chronic rhinosinusitis (CRS) with a high symptom burden. Doxycycline can be used as add-on therapy in CRSwNP. We aimed to evaluate short-term efficacy of oral doxycycline on visual analog scale (VAS) and SNOT-22 (Sino-nasal outcome test) score for CRSwNP.
Visual analog score (VAS) for nasal symptoms and total SNOT-22 scores of 28 patients who applied with the diagnosis of CRSwNP and received 100 mg doxycycline for 21 days were analyzed in this retrospective cohort study. Doxycycline efficacy was also evaluated in subgroups determined according to asthma, presence of atopy, total IgE and eosinophil levels.
After 21-day doxycycline treatment, there was a significant improvement in VAS score for post-nasal drip, nasal discharge, nasal congestion, and sneeze, and total SNOT-22 score (p = 0.001, p < 0.001, p < 0.001, p < 0.001, p < 0.001, respectively). No significant improvement was observed in VAS score for the loss of smell (p = 0.18). In the asthmatic subgroup, there were significant improvements in all VAS scores and total SNOT-22 score after doxycycline. In the non-asthmatic subgroup, there was no significant change in any of the VAS scores, but total SNOT-22 score was significantly improved (42 [21-78] vs. 18 [9-33]; p = 0.043). Improvement in VAS score for loss of smell is significant in only some subgroups like asthmatic patients, non-atopic patients, and patients with eosinophil >300 cell/µL.
Doxycycline can be considered as an add-on treatment for symptom control in patients especially with CRSwNP comorbid with asthma.
Visual analog score (VAS) for nasal symptoms and total SNOT-22 scores of 28 patients who applied with the diagnosis of CRSwNP and received 100 mg doxycycline for 21 days were analyzed in this retrospective cohort study. Doxycycline efficacy was also evaluated in subgroups determined according to asthma, presence of atopy, total IgE and eosinophil levels.
After 21-day doxycycline treatment, there was a significant improvement in VAS score for post-nasal drip, nasal discharge, nasal congestion, and sneeze, and total SNOT-22 score (p = 0.001, p < 0.001, p < 0.001, p < 0.001, p < 0.001, respectively). No significant improvement was observed in VAS score for the loss of smell (p = 0.18). In the asthmatic subgroup, there were significant improvements in all VAS scores and total SNOT-22 score after doxycycline. In the non-asthmatic subgroup, there was no significant change in any of the VAS scores, but total SNOT-22 score was significantly improved (42 [21-78] vs. 18 [9-33]; p = 0.043). Improvement in VAS score for loss of smell is significant in only some subgroups like asthmatic patients, non-atopic patients, and patients with eosinophil >300 cell/µL.
Doxycycline can be considered as an add-on treatment for symptom control in patients especially with CRSwNP comorbid with asthma.
摘要：
■慢性鼻窦炎伴鼻息肉（CRSwNP）是慢性鼻窦炎（CRS）的主要表型之一，具有高症状负担。强力霉素可用作CRSwNP的附加疗法。我们的目的是评估口服多西环素对CRSwNP的视觉模拟评分（VAS）和SNOT-22（鼻塞结局测试）评分的短期疗效。
■在这项回顾性队列研究中，分析了28例诊断为CRSwNP并接受100mg多西环素治疗21天的患者的鼻部症状的视觉模拟评分（VAS）和SNOT-22总分。还在根据哮喘确定的亚组中评估了强力霉素的疗效，特应性的存在，总IgE和嗜酸性粒细胞水平。
■强力霉素治疗21天后，鼻后滴注的VAS评分有显著改善，鼻腔分泌物,鼻塞,打喷嚏,和SNOT-22总评分（分别为p=0.001，p<0.001，p<0.001，p<0.001，p<0.001）。在气味损失的VAS评分中没有观察到显著改善(p=0.18)。在哮喘亚组中，多西环素治疗后所有VAS评分和SNOT-22总分均有显著改善.在非哮喘亚组中，任何VAS评分都没有显著变化，但SNOT-22总得分显着提高（42[21-78]vs.18[9-33]；p=0.043）。仅在某些亚组（如哮喘患者）中，嗅觉丧失的VAS评分的改善才显着。非特应性患者，和嗜酸性粒细胞>300细胞/微升的患者。
■多西环素可被认为是控制症状的附加治疗，尤其是CRSwNP合并哮喘患者。
■在这项回顾性队列研究中，分析了28例诊断为CRSwNP并接受100mg多西环素治疗21天的患者的鼻部症状的视觉模拟评分（VAS）和SNOT-22总分。还在根据哮喘确定的亚组中评估了强力霉素的疗效，特应性的存在，总IgE和嗜酸性粒细胞水平。
■强力霉素治疗21天后，鼻后滴注的VAS评分有显著改善，鼻腔分泌物,鼻塞,打喷嚏,和SNOT-22总评分（分别为p=0.001，p<0.001，p<0.001，p<0.001，p<0.001）。在气味损失的VAS评分中没有观察到显著改善(p=0.18)。在哮喘亚组中，多西环素治疗后所有VAS评分和SNOT-22总分均有显著改善.在非哮喘亚组中，任何VAS评分都没有显著变化，但SNOT-22总得分显着提高（42[21-78]vs.18[9-33]；p=0.043）。仅在某些亚组（如哮喘患者）中，嗅觉丧失的VAS评分的改善才显着。非特应性患者，和嗜酸性粒细胞>300细胞/微升的患者。
■多西环素可被认为是控制症状的附加治疗，尤其是CRSwNP合并哮喘患者。
